<DOC>
	<DOCNO>NCT00463372</DOCNO>
	<brief_summary>To evaluate safety tolerability multiple dose PF-02545920 subject schizophrenia schizo-affective disorder currently clinically stable evaluate serum urine pharmacokinetics PF-02545920 N-desmethyl metabolite , PF-01001252 , multiple dos PF-02545920 administer orally .</brief_summary>
	<brief_title>Study Investigating Safety Tolerability Multiple Doses PF-02545920 Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Subjects DSMIV diagnosis schizophrenia schizoaffective disorder antipsychotic monotherapy indicate . Subjects must free acute exacerbation psychosis least 3 month prior screen . Current Clinical Global Impression ( CGI ) Severity Illness score ≤3 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , neurological , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Evidence history primary DSMIV axis I diagnosis schizophrenia schizoaffective disorder . Any condition possibly affect drug absorption ( e.g. , gastrectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>